Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study

Addiction

Volumn 112, Issue 12, 2017, Pages 2191-2201

  Darke, Shane ^a   Kaye, Sharlene ^a,b   Duflou, Johan ^a,c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b New South Wales Government   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Circumstances; disease; epidemiology; methamphetamine; mortality; toxicity

Indexed keywords

METHAMPHETAMINE;

ADULT; AMPHETAMINE DEPENDENCE; AUSTRALIA; BLOOD; CAUSE OF DEATH; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MORTALITY; QUESTIONNAIRE;

ADULT; AMPHETAMINE-RELATED DISORDERS; AUSTRALIA; CAUSE OF DEATH; FEMALE; HUMANS; MALE; METHAMPHETAMINE; SURVEYS AND QUESTIONNAIRES;

EID: 85023206831     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13897     Document Type: Article

References (50)

1. United Nations Office on Drugs and Crime. World Drug Report 2016. New York: United Nations; 2016.
2. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012; 379: 55–70.
3. Degenhardt L., Whiteford H. A., Ferrari A. J., Baxter A. J., Charlson F. J., Hall W. D. et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease study 2010. Lancet 2013; 382: 1564–1574.
4. Topp L., Degenhardt L., Kaye S., Darke S. The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system. Drug Alcohol Rev 2002; 21: 341–348.
5. Lai F. Y., O'Brien J., Thai P. K., Hall W. D., Mueller J. Trends in methamphetamine residues in wastewater in metropolitan and regional cities in South East Queensland, 2009–2015. Med J Aust 2016; 204: 151–152.
6. Degenhardt L., Larney S., Chan G., Dobbins T., Weier M., Roxburgh A. et al. Estimating the number of regular and dependent methamphetamine users in Australia, 2002–2014. Med J Aust 2016; 204: 153–158.
7. Karch S. B., Stephens B. G., Ho C. H. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicological profiles. J Forensic Sci 1999; 44: 359–368.
8. McKetin R., Najman J. M., Baker A. L., Lubman D. I., Dawe S., Ali R. et al. Evaluating the impact of community-based treatment options on methamphetamine use: findings from the methamphetamine treatment evaluation study (MATES). Addiction 2012; 107: 1998–2008.
9. Zhu B. L., Oritani S., Shimotouge K., Ishida K., Quan L., Fujita M. Q. et al. Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas. Forensic Sci Int 2000; 113: 443–447.
10. McKetin R., Kelly E., McLaren J. The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug Alcohol Depend 2006; 85: 198–204.
11. Marshall B. D., Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction 2010; 105: 991–1002.
12. McKetin R., Kelly E., McLaren J., Proudfoot H. Impaired physical health among methamphetamine users in comparison with the general population: the role of methamphetamine dependence and opioid use. Drug Alcohol Rev 2008; 27: 482–489.
13. Darke S., Kaye S., McKetin R., Duflou J. The major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 2008; 27: 253–262.
14. Darke S., Torok M., Kaye S., Duflou J. Cardiovascular disease risk factors and symptoms amongst regular psychostimulant users. Drug Alcohol Rev 2010; 29: 371–377.
15. Karch S. B. Karch's Pathology of Drug Abuse, 4th edn. Boca Raton: CRC Press; 2009.
16. Karch S. B. The unique histology of methamphetamine cardiomyopathy: a case report. Forensic Sci Int 2011; 212: e1–e4.
17. Kaye S., McKetin R., Duflou J., Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007; 102: 1204–1211.
18. Neeki M. M., Kulczycki M., Toy J., Dong F., Lee C., Borger R. et al. Frequency of methamphetamine use as a major contributor toward the severity of cardiomyopathy in adults ≤ 50 years. Am J Cardiol 2016; 118: 585–589.
19. Voskoboinik A., Ihl J. F., Bloom J. E., Kaye D. M. Methamphetamine-associated cardiomyopathy: patterns and predictors of recovery. Intern Med J 2016; 46: 723–727.
20. Moon K., Albuquerque F. C., Mitkov M., Ducruet A. F., Wilson D. A., Crowley R. W. et al. Methamphetamine use is an independent predictor of poor outcome after aneurysmal subarachnoid haemorrhage. J Neurointerv Surg 2015; 7: 346–350.
21. Westover A. N., McBride S., Haley R. W. Stroke in young adults who abuse amphetamines or cocaine. Arch Gen Psychiatry 2007; 64: 495–502.
22. Darke S., Torok M., McKetin R., Kaye S., Ross J. Patterns of psychological distress related to regular methamphetamine and opioid use. Addict Res Theory 2011; 19: 121–127.
23. Lappin J. M., Roxburgh A., Kaye S., Chalmers J., Sara G., Dobbins T. et al. Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: evidence from a high-risk population. Int J Drug Policy 2016; 38: 16–20.
24. McKetin R., Hickey K., Devlin K., Lawrence K. The risk of psychotic symptoms associated with recreational methamphetamine use. Drug Alcohol Rev 2010; 29: 358–363.
25. McKetin R., McLaren J., Lubman D. I., Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101: 1473–1478.
26. Darke S., Torok M., Kaye S., Ross J., McKetin R. Comparative rates of violent crime amongst regular methamphetamine and opioid users: offending and victimization. Addiction 2010; 105: 916–919.
27. Logan B., Fligner C. L., Haddix T. Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 1998; 43: 28–34.
28. Sommers I., Baskin D., Baskin-Sommers A. Methamphetamine use among young adults: health and social consequences. Addict Behav 2006; 31: 1469–1476.
29. Zweben J. E., Cohen J. B., Christian D., Galloway G. P., Salinardi M., Parent D. et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13: 81–90.
30. Arendt M., Munk-Jørgensen P., Sher L., Jensen S. O. Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: a nationwide follow-up study of Danish substance users in treatment. Drug Alcohol Depend 2011; 114: 134–139.
31. Callaghan R. C., Cunningham J. K., Verdichevski M., Sykes J., Jaffer S. R., Kish S. J. All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. Drug Alcohol Depend 2012; 125: 290–294.
32. Kuo C. J., Liao Y. T., Chen W. J., Tsai S., Lin S., Chen C. C. Causes of death of patients with methamphetamine dependence: a record-linkage study. Drug Alcohol Rev 2011; 30: 621–628.
33. Singleton J., Degenhardt L., Hall W., Zabransky T. Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend 2009; 105: 1–8.
34. Stenbacka M., Liefman L., Romelsjo A. Mortality and cause of death among 1705 illicit drug users, a 37 year follow-up. Drug Alcohol Rev 2010; 29: 21–27.
35. Kaye S., Darke S., McKetin R., Duflou J. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. Addiction 2008; 103: 1353–1360.
36. Mendelson J., Jones R. T., Upton R., Jacob P. Methamphetamine and ethanol interactions in humans. Clin Pharm Ther 1995; 57: 559–568.
37. Buckley N. A., Dawson A. H., Isbister G. K. Serotonin syndrome. BMJ 2014; 348: g1626.
38. Pilgrim J. L., Gerostamoulos D., Drummer O. H. Deaths involving serotonergic drugs. Forensic Sci Int 2010; 198: 110–117.
39. Sansone R. A., Sansone L. A. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry 2009; 6: 17–21.
40. Australian Bureau of Statistics. Australian Demographic Statistics, 3101.0. Canberra: Australian Bureau of Statistics; 2016.
41. Australian Bureau of Statistics. Deaths in Australia, 2014, Vol. 2015. Canberra: Australian Bureau of Statistics.
42. IBM Inc. SPSS Statistics, 23.0. Chicago: IBM Inc.; 2015.
43. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2016.
44. Calcaterra S., Binswanger I. A. National trends in psychostimulant-related deaths: 1999–2009. Subst Abuse 2013; 34: 129–136.
45. Darke S., Marel C., Mills K. L., Ross J., Slade T., Tessson M. Years of potential life lost amongst heroin users in the Australian treatment outcome study cohort, 2001–2015. Drug Alcohol Depend 2016; 162: 206–210.
46. Darke S., Duflou J., Torok M. The comparative toxicology and major organ pathology of fatal methadone and heroin toxicity cases. Drug Alcohol Depend 2010; 106: 1–6.
47. Shibata S., Sekine I., Suyama H. Subarachnoid and intracerebral haemorrhage associated with necrotizing angiitis due to methamphetamine abuse. Neurol Med Chir 1991; 31: 49–52.
48. Callanan V. J., Davis M. S. Gender differences in suicide methods. Soc Psychiatry Psychiatr Epidemiol 2012; 47: 857–869.
49. Darke S., Ross J. The relationship between suicide and overdose among methadone maintenance patients in Sydney, Australia. Addiction 2001; 96: 1443–1453.
50. Darke S., Farrell M. Which medications are suitable for agonist drug maintenance? Addiction 2016; 111: 767–774.